Curis Inc (CRIS, Financial) experienced a significant stock movement with a 6.19% increase in price, reaching $3.26 per share. The trading volume was 39,453 shares, with a turnover rate of 0.47% and the same percentage in price fluctuation. Recent financial reports revealed revenue of $2.93 million and a net loss of $10.09 million, resulting in an earnings per share of -$1.70 and a gross profit of $2.85 million. The price-to-earnings ratio stands at -0.41.
Among five institutions rating the stock, 80% recommended buying, while 20% suggested holding, with no sell recommendations. In the broader biotechnology sector, the overall increase was 0.68%. Noteworthy stocks in the sector include Abpro Holdings Inc and Aptose Biosciences Inc, which showed significant activity and turnover rates.
Curis Inc is a biotechnology company focused on developing innovative drugs in immuno-oncology and precision oncology, targeting various cancers including solid tumors and lymphomas.
